No Differences in Achieving Hepatitis C Virus Care Milestones Between Patients Identified by Birth Cohort or Risk-Based Screening

Norton, Brianna L.; Southern, William N.; Steinman, M.; Smith, Bryce D.; Rosner, Zachary; Litwin, Alain H.

doi:10.1016/j.cgh.2016.04.017

Cited by 12 publications

(13 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar to our findings, a study of HCV care milestones achieved by HCV antibody-positive patients in three community-based primary care clinics in the Bronx, New York, identified multiple deficiencies in the HCV cascade of care 32 . More than 20% of HCV antibody-positive patients identified through risk-based and birth cohort screening in their study did not receive confirmatory viral load testing to determine chronic infection.…”

Section: Discussionsupporting

confidence: 84%

Integrating hepatitis C care for at-risk groups (HepLink): baseline data from a multicentre feasibility study in primary and community care

Riogh

Swan

McCombe

et al. 2019

Journal of Antimicrobial Chemotherapy

View full text Add to dashboard Cite

Objectives To examine HCV prevalence and management among people who inject drugs (PWID) attending primary care and community-based health services at four European sites using baseline data from a multicentre feasibility study of a complex intervention (HepLink). Methods Primary care and community-based health services in Dublin, London, Bucharest and Seville were recruited from the professional networks of the HepLink consortium. Patients were eligible to participate if aged ≥18 years, on opioid substitution treatment or at risk of HCV (i.e. injecting drug use, homeless or incarcerated), and attended the service. Data on patient demographics and prior HCV management were collected on participants at baseline. Results Twenty-nine primary care and community-based health services and 530 patients were recruited. Baseline data were collected on all participants. Participants’ mean age ranged from 35 (Bucharest) to 51 years (London), with 71%–89% male. Prior lifetime HCV antibody testing ranged from 65% (Bucharest) to 95% (Dublin) and HCV antibody positivity among those who had been tested ranged from 78% (Dublin) to 95% (Bucharest). Prior lifetime HCV RNA testing among HCV antibody-positive participants ranged from 17% (Bucharest) to 84% (London). Among HCV antibody- or RNA-positive participants, prior lifetime attendance at a hepatology/infectious disease service ranged from 6% (London) to 50% (Dublin) and prior lifetime HCV treatment initiation from 3% (London) to 33% (Seville). Conclusions Baseline assessment of the HCV cascade of care among PWID attending primary care and community-based health services at four European sites identified key aspects of the care cascade at each site that need to be improved.

show abstract

Section: Discussionsupporting

confidence: 84%

Integrating hepatitis C care for at-risk groups (HepLink): baseline data from a multicentre feasibility study in primary and community care

Riogh

Swan

McCombe

et al. 2019

Journal of Antimicrobial Chemotherapy

View full text Add to dashboard Cite

show abstract

“…For all sites of diagnosis, a fairly high portion of those patients that were linked to care actually started treatment for HCV, from a low of 32% of those diagnosed in CID to a high of 54% from GIM. Overall, this is higher than rates identified in other settings [15, 20]. It is thought that this is due to an overall high capacity and high commitment to treating HCV at our institution.…”

Section: Discussionmentioning

confidence: 61%

HCV screening, linkage to care, and treatment patterns at different sites across one academic medical center

et al. 2019

View full text Add to dashboard Cite

Background It is unclear whether sites that screen large numbers of patients for Hepatitis C Virus but achieve limited follow-up are more or less effective at having patients succeed through linkage and treatment than lower volume sites that have higher linkage percentages. The objective was to compare the rates of HCV identification, linkage to care, and treatment success between different study sites including the Emergency Department, 3 outpatient clinics with unique patients, and the inpatient setting at one medical center Methods This is a descriptive analysis of 2 years of data from a protocol that integrated HCV screening and treatment into clinical services throughout multiple departments in one medical center. The program used a best practice advisory to prompt testing at all sites, with different triggers for it to fire at each site, and one central navigation program that attempted to link all patients diagnosed with hepatitis C virus to outpatient care. Outcomes included volume of tests performed in each site, Antibody and RNA rates at each site, demographic data, navigation and linkage outcomes, and post-linkage treatment completion. Results 28,435 patients were screened across 5 clinical locations. RNA+ rates and absolute numbers linked to MD (linkage rates among all RNA+) were: ED 7.2% RNA+, 224 (22.6%) linked; Inpatient 14.8% RNA+, 27 (17.6%) linked, General Internal Medicine 3.9% RNA+, 269 (65.8%) linked, Infectious Diseases 4.0% RNA+, 34(70.8%) linked, Family Medicine 2.0% RNA+, 28 (75.7%) linked. Demographics, linkage barriers, and treatment initiation rates were different at all sites. Conclusion Among sites there were differences in the sociodemographic characteristics of patients diagnosed with HCV, as well as differences in the success linking patients to outpatient care. At this medical center, the ED screened the most patients, the inpatient area had the highest RNA positivity rate, the FM clinic had the highest linkage rate, GIM linked the most patients by absolute number, and GIM also had the highest number of patients start treatment.

show abstract

“…We study (23,26), The Hepatitis C Assessment and Testing (HepCAT) project (59)(60)(61), and The Hepatitis C: Assessment through to Treatment (HepCATT) study (62,63), and more recent studies in the Netherlands (64), Ukraine (65) and Scotland (66) are based in single countries or outside Europe, are focused on particular points in the HCV cascade of care (e.g. testing and referral or evaluation and treatment), and do not include the broad range of settings that Hepcare will.…”

Section: Discussionmentioning

confidence: 99%

Hepcare Europe - bridging the gap in the treatment of hepatitis C: study protocol

Swan

Cullen

Macı́as

et al. 2018

Expert Review of Gastroenterology & Hepatology

View full text Add to dashboard Cite

show abstract

No Differences in Achieving Hepatitis C Virus Care Milestones Between Patients Identified by Birth Cohort or Risk-Based Screening

Cited by 12 publications

References 14 publications

Integrating hepatitis C care for at-risk groups (HepLink): baseline data from a multicentre feasibility study in primary and community care

Integrating hepatitis C care for at-risk groups (HepLink): baseline data from a multicentre feasibility study in primary and community care

HCV screening, linkage to care, and treatment patterns at different sites across one academic medical center

Hepcare Europe - bridging the gap in the treatment of hepatitis C: study protocol

Contact Info

Product

Resources

About